Fairvalue-Calculator Fairvalue-Calculator
EN DE

Aton (ALTAO) Fair Value & Analysis

Healthcare · FR · Market cap €15.3M

Price€0.0110
Fair Value€0.0100
Upside-9.1%
Quality86/100
Evidence: Medium

Fair value as of: Jun 23, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Aton (ALTAO) currently trades at €0.0110, while our model-based Fair Value estimate is €0.0100 — implying the stock looks roughly 9.1% overvalued today. We read business quality at 86/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Aton operates as a bioscience company in France. It engages in drug development, preclinical and clinical services, production of monoclonal antibodies, laboratory equipment production, and designing and manufacturing of medical devices, as well as provision of human tissues. The company also offers medical devices for surgeons, powered by Stemcis. The company was founded in 1998 and is headquartered in Strasbourg, France.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Aton (ALTAO) undervalued?
As of Jun 23, 2026, our model estimates a fair value of €0.0100 versus a price of €0.0110 — about −9% (overvalued). Model-based estimate, not financial advice.
What is the fair value of ALTAO?
Our 21-model fair value for Aton is €0.0100 (as of Jun 23, 2026), built from audited fundamentals. The current price is €0.0110.
What is the quality score of ALTAO?
Aton has a Quality Score of 86/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.